

## Corrigendum—Full Exemption of Certain COVID-19 Point-of-care Tests Under the COVID-19 Public Health Response (Point-of-care Tests) Order 2021

Pursuant to clause 9 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, Dr Ashley Bloomfield, Director-General of Health, exempt the following point-of-care rapid antigen tests from all prohibitions under clause 7 of the Order.

<p><b>Product name(s):</b> StrongStep SARS-CoV-2 Antigen Rapid Test</p> <p><b>Manufacturer (country):</b> Nanjing Liming Bio-Products Co., Ltd (China)</p> <p><b>Sample type(s):</b> Nasal swab</p> <p><b>Product configuration:</b> Professional or self-test of any package size</p>
<p><b>Product name(s):</b> CLUNGENE COVID-19 Antigen Rapid Test</p> <p><b>Manufacturer (country):</b> Hangzhou Clongene Biotech Co., Ltd (China)</p> <p><b>Sample type(s):</b> Nasal swab</p> <p><b>Product configuration:</b> Self-test of any package size</p>
<p><b>Product name(s):</b> INDICAID COVID-19 Rapid Antigen Test</p> <p><b>Manufacturer (country):</b> PHASE Scientific International, Ltd. (Hong Kong and United States of America)</p> <p><b>Sample type(s):</b> Nasal swab</p> <p><b>Product configuration:</b> Professional or self-test of any package size</p>

Dated at Wellington this 28th day of April 2022.

DR ASHLEY BLOOMFIELD, Director-General of Health, Ministry of Health.

*Note:* This notice replaces the notice published in the [New Zealand Gazette, 29 April 2022, Notice No. 2022-go1608](#).